Advertisement

Topics

TiGenix NV Company Profile

11:04 EDT 20th June 2018 | BioPortfolio

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an advanced clinical stage pipeline of adult stem cell programs.
The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched in different European countries.
TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.  The company has initiated a Phase III clinical trial in complex perianal fistulas in patients with Crohn’s disease, is conducting a Phase IIa trial in rheumatoid arthritis, and successfully concluded a Phase I trial to investigate the potential of intra-lymphatic administration of eASCs for autoimmune disorders.
TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).

Location

Haasrode Researchpark 1724
Romeinse straat 12 bus 2
Leuven
Leuven
B-3001
Belgium

Contact

Phone: +32 (0) 16 39 60 60
Fax: +32 (0) 16 39 79 70
Email: info@tigenix.com


News Articles [82 Associated News Articles listed on BioPortfolio]

Takeda Announces Intention to Acquire Cell Therapy Firm TiGenix

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced its intention to acquire TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”), an advanced biopharmaceutical ...

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix

Takeda Pharmaceutical (TSE:4502) and TiGenix (Euronext Brussels and Nasdaq:TIG) today announced the results of the first acceptance period of Takeda’s previously announced tender offer in cash f...

TiGenix: TiGenix: Transparency Information

PRESS RELEASEREGULATED INFORMATION Transparency Information Leuven (BELGIUM) - February 6, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance wit...

Takeda buys TiGenix for €517mm

Takeda Pharmaceutical Co. Ltd. agreed to acquire the remaining shares of regenerative medicine partner TiGenix NV that it does not already own through a voluntary takeover bid that has the support of ...

Takeda agrees $630m takeover of TiGenix

Takeda already had a strong working relationship with TiGenix, after previously signing a licensing agreement with the Belgium-based pharma company on a treatment for Crohn’s disease. It has now mov...

TiGenix: TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601

PRESS RELEASE TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 Leuven (BELGIUM) - January 15, 2018, 07:00 CET - TiGenix NV (Euronext B...

TiGenix: TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

REGULATED INFORMATIONPRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 26, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and N...

TiGenix: TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

REGULATED INFORMATIONPRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 18, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Na...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

TiGenix NV

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an advanced clinical stage pipeline of adult stem cell programs. The company’s lead pr...

Ysios Capital

Ysios Capital is an independent venture capital firm providing private equity financing to early through late-stage human healthcare and biotechnology companies with special focus...

More Information about "TiGenix NV" on BioPortfolio

We have published hundreds of TiGenix NV news stories on BioPortfolio along with dozens of TiGenix NV Clinical Trials and PubMed Articles about TiGenix NV for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TiGenix NV Companies in our database. You can also find out about relevant TiGenix NV Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record